phrykt

Immunome Inc. (IMNM): who owns it and who trades it

As of Nov 16, 2026, IMNM insiders reported 28 open-market sales worth $27.5M and 11 purchases worth $2.3M in the last 12 months, with 94% of the sale value made under pre-set 10b5-1 plans. The largest seller was Isaac Barchas (Director), with $18.3M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Immunome

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IMNM

203 funds and institutions reported IMNM shares worth $2.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is T. Rowe Price Investment Management, Inc. with 17.4%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

T. Rowe Price Investment Management, Inc.17.4%
FMR LLC (Fidelity)15.0%
BlackRock, Inc.7.8%
State Street Corp4.9%
Wellington Management Group LLP4.6%
Redmile Group, LLC4.3%
Primecap Management Co4.0%
Vanguard Capital Management LLC4.0%
Driehaus Capital Management LLC3.8%
Enavate Sciences Gp, LLC3.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
T. Rowe Price Investment Management, Inc.19.68M17.39%$417M+20%
FMR LLC (Fidelity)16.99M15.02%$360M+0%
BlackRock, Inc.8.81M7.78%$187M+8%
State Street Corp5.49M4.86%$116M+2%
Wellington Management Group LLP5.21M4.61%$110M+10%
Redmile Group, LLC4.91M4.34%$104M-12%
Primecap Management Co4.58M4.05%$97.1M-4%
Vanguard Capital Management LLC4.55M4.02%$96.4M+3%
Driehaus Capital Management LLC4.35M3.84%$92.1M+6%
Enavate Sciences Gp, LLC3.61M3.19%$76.6MNo change
Geode Capital Management, LLC2.75M2.44%$58.4M+8%
Morgan Stanley2.41M2.13%$51M-15%
California State Teachers Retirement System2.29M2.03%$108M+1958%
Silverarc Capital Management, LLC2.02M1.78%$42.7M+9%
JPMorgan Chase & Co1.85M1.63%$39M–
T. Rowe Price Associates1.77M1.57%$37.6M-38%
Sofinnova Investments, Inc.1.72M1.52%$36.5M+1%
Readystate Asset Management LP1.61M1.42%$34M+23%
Goldman Sachs Group Inc1.51M1.34%$32M+37%
Vanguard Portfolio Management LLC1.35M1.19%$28.6M+34%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, IMNM insiders reported $2.3M of open-market purchases and $27.5M of sales. 94% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$2.3M
11 trades, 3 people
Sales, 12 months
$27.5M
28 trades, 7 people
Sales under a 10b5-1 plan
94%
Share of sale value
Latest trade
Sep 11, 2026
Filed Sep 15, 2026

Purchases and sales by month

$8.3M$8.3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 11, 2026Jack HigginsChief Scientific OfficerSale plan13,200$25.32$334KForm 4
Aug 12, 2026Isaac BarchasDirectorSale plan11,048$27.25$301KForm 4
Aug 11, 2026Isaac BarchasDirectorSale plan62,291$26.23$1.6MForm 4
Aug 10, 2026Isaac BarchasDirectorSale plan10,125$26.07$264KForm 4
Aug 7, 2026Isaac BarchasDirectorSale plan15,248$26.06$397KForm 4
Aug 6, 2026Isaac BarchasDirectorSale plan20,840$26.06$543KForm 4
Aug 4, 2026Kinney HornCHIEF BUSINESS OFFICERSale plan90,616$25.09$2.3MForm 4
Jul 7, 2026Kinney HornCHIEF BUSINESS OFFICERSale plan1,092$25.00$27.3KForm 4
Jul 7, 2026Isaac BarchasDirectorSale plan16,906$24.20$409KForm 4
Jul 6, 2026Isaac BarchasDirectorSale plan83,094$24.11$2MForm 4
Jul 2, 2026Robert LechleiderChief Medical OfficerSale plan16,072$23.44$377KForm 4
Jul 2, 2026Robert LechleiderChief Medical OfficerSale plan16,214$22.76$369KForm 4
Jul 2, 2026Robert LechleiderChief Medical OfficerSale plan22,714$21.95$499KForm 4
Jul 2, 2026Isaac BarchasDirectorSale plan75,665$22.35$1.7MForm 4
Jul 2, 2026Isaac BarchasDirectorSale plan24,335$23.33$568KForm 4
Jun 30, 2026Isaac BarchasDirectorSale plan101,050$21.12$2.1MForm 4
Jun 25, 2026Robert LechleiderChief Medical OfficerSale plan40,580$19.56$794KForm 4
Jun 25, 2026Robert LechleiderChief Medical OfficerSale plan14,420$20.66$298KForm 4
Jun 15, 2026Max RosettCFOSale plan60,000$18.23$1.1MForm 4
Jun 5, 2026Jean Jacques BienaimeDirectorSale500$19.44$9.7KForm 4
Jun 5, 2026Jean Jacques BienaimeDirectorSale10,000$19.41$194KForm 4
Jun 5, 2026Jean Jacques BienaimeDirectorPurchase6,000$19.48$117KForm 4
Jun 5, 2026Jean Jacques BienaimeDirectorPurchase3,500$19.46$68.1KForm 4
Jun 5, 2026Jean Jacques BienaimeDirectorPurchase1,000$19.27$19.3KForm 4
May 15, 2026Jean Jacques BienaimeDirectorPurchase5,000$20.70$104KForm 4
Apr 2, 2026Jack HigginsChief Scientific OfficerSale plan9,438$21.64$204KForm 4
Apr 2, 2026Max RosettCFOSale plan1,344$22.48$30.2KForm 4
Apr 2, 2026Max RosettCFOSale plan63,656$21.91$1.4MForm 4
Mar 27, 2026Clay B SiegallCEOPurchase25,450$19.67$501KForm 4
Mar 23, 2026Philip WagenheimDirectorSale28,200$20.65$582KForm 4
Mar 20, 2026Philip WagenheimDirectorSale36,800$20.47$753KForm 4
Mar 11, 2026Jean Jacques BienaimeDirectorPurchase1,000$21.55$21.6KForm 4
Mar 10, 2026Jean Jacques BienaimeDirectorPurchase1,000$22.12$22.1KForm 4
Dec 30, 2025Clay B SiegallCEOPurchase4,729$21.15$100KForm 4
Dec 22, 2025Isaac BarchasDirectorSale plan371,949$21.72$8.1MForm 4
Dec 22, 2025Isaac BarchasDirectorSale plan11,251$22.34$251KForm 4
Dec 19, 2025Clay B SiegallCEOPurchase7,278$20.48$149KForm 4
Dec 19, 2025Philip TsaiChief Technical OfficerPurchase10,000$20.49$205KForm 4
Dec 18, 2025Clay B SiegallCEOPurchase46,511$21.50$1000KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Isaac BarchasDirector–$18.3MAug 12, 2026
Max RosettChief Financial Officer–$2.5MJun 15, 2026
Robert LechleiderChief Medical Officer–$2.3MJul 2, 2026
Kinney HornCHIEF BUSINESS OFFICER–$2.3MAug 4, 2026
Clay B SiegallPresident and CEO, Director$1.7M–Mar 27, 2026
Philip WagenheimDirector–$1.3MMar 23, 2026
Jean Jacques BienaimeDirector$351K$204KJun 5, 2026
Jack HigginsChief Scientific Officer–$538KSep 11, 2026
Philip TsaiChief Technical Officer$205K–Dec 19, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IMNM short interest

High short interest. 14.2% of IMNM shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went down 8%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 16.17M IMNM shares were sold short, 14.2% of the shares outstanding, down 6.4% from the report before. At the average daily volume of 1.27M shares, buying them all back would take about 12.8 trading days (days to cover).

Shares short, % of all shares

14.2%May 15Oct 3016.4%

Days to cover

12.8May 15Oct 3025.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202616.17M14.24%-6%1.27M12.8
Oct 15, 202617.28M15.22%+3%1.42M12.2
Sep 30, 202616.76M14.75%+3%1.69M9.9
Sep 15, 202616.24M14.30%+4%787,59820.6
Aug 31, 202615.63M13.77%-10%1.24M12.6
Aug 14, 202617.39M15.31%-3%1.17M14.9
Jul 31, 202617.98M15.89%+4%782,63823.0
Jul 15, 202617.24M15.24%-1%1.64M10.5
Jun 30, 202617.37M15.35%-4%2.14M8.1
Jun 15, 202618.15M16.04%+8%1.40M12.9
May 29, 202616.86M14.91%-4%1.19M14.2
May 15, 202617.63M15.58%-6%878,98720.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Immunome company events

Immunome filed 8 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Oct 5, 2026AgreementImmunome, Inc. entered into Amendment No. 4 to License Agreement with Bristol-Myers Squibb Company to further amend the License Agreement, by and between BMS and the Company (as assignee of Ayala Pharmaceuticals, Inc.), dated as of November 29, 2017 (as amended, the “License Agreement”). Filing
  3. Aug 11, 2026ResultsReleased financial results. Filing
  4. Jun 12, 2026VoteReported shareholder vote results. Filing
  5. May 12, 2026ResultsReleased financial results. Filing
  6. Mar 3, 2026ResultsReleased financial results. Filing
  7. Dec 17, 2025AnnouncementImmunome, Inc. entered into an underwriting agreement with Leerink Partners LLC, J.P. Morgan Securities LLC, TD Securities (USA) LLC, Goldman Sachs & Co. LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein, relating to the issuance and sale in a public… Filing
  8. Dec 15, 2025AnnouncementImmunome, Inc. (the Company, we or our) announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoid tumors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Immunome financials

Famous investors that hold IMNM

3 of the 50 well-known investors we track reported holding IMNM in their latest 13F filing. The largest position is Ken Griffin's, worth $10.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026473,537$10.2M0.0%+111%
Israel Englander · Millennium ManagementQ3 202662,191$1.3M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202635,170$757K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named IMNM in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Wellington Management Group LLP13G5.3%
Nov 16, 2026Wellington Management Group LLP13G5.3%
Oct 30, 2026Vanguard Capital Management13G5.0%
Oct 30, 2026Vanguard Capital Management13G5.0%

Questions about Immunome Inc. (IMNM) stock

Who owns the most IMNM stock?

The largest reported owner of Immunome Inc. (IMNM) is T. Rowe Price Investment Management, Inc., with 17.4% of the company. In total, 203 funds and institutions reported holding IMNM at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are IMNM insiders buying or selling?

In the last 12 months, IMNM insiders reported 11 open-market purchases worth $2.3M and 28 sales worth $27.5M. The latest trade was on Sep 11, 2026. See every trade.

What is the short interest in IMNM?

As of Oct 30, 2026, 16.17M IMNM shares were sold short, 14.2% of the shares outstanding, down 6.4% from the report before. At the average daily volume of 1.27M shares, buying them all back would take about 12.8 trading days (days to cover). See the history.

Which famous investors hold IMNM?

3 of the 50 well-known investors we track reported IMNM in their latest 13F filing, including Ken Griffin, Israel Englander, Paul Tudor Jones. The largest position is worth $10.2M. See all holders.

Executive pay

Immunome's chief executive was paid a total of $7.7M for the year ended Dec 31, 2025, down 17% from $9.2M the year before. In the last 12 months, Immunome's executives and directors bought $2.3M of stock on the open market and sold $27.5M.

Chief executive, total pay$7.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$28.1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.8MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.